Retatrutide Prescribed Online to Rhode Island Residents
Medical Weight Loss Treatment in Rhode Island
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Key Benefits
- Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
- Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
- ~58% hepatic fat reduction in Phase 2 sub-group analyses
- Elevated basal metabolic rate via glucagon receptor agonism
- Research-grade purity ≥98% with full CoA, HPLC, and MS documentation
Who is a Good Candidate?
Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.
Available for research use
Serving Rhode Island
Rhode Island may be the smallest state, but its healthcare needs are mighty. OmniRx Health serves the entire Ocean State—from Providence's universities to Newport's waterfront, the mill towns of the Blackstone Valley to the beaches of South County. Our telehealth platform is perfect for Rhode Islanders who value efficiency—why sit in traffic on Route 95 or wait weeks for an appointment when you can connect with a board-certified provider from anywhere?
OmniRx Health providers are licensed by the Rhode Island Board of Medical Licensure and Discipline for statewide telehealth.
Rhode Island pharmacies throughout Providence, Newport, and the entire state ensure quick prescription access and delivery.
Rhode Island has progressive telehealth laws that support comprehensive virtual care delivery throughout the Ocean State.
Rhode Island mandates telehealth coverage parity, ensuring virtual visits are covered like in-person appointments.
Frequently Asked Questions
- What is retatrutide and how does it work?
- Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
- How does retatrutide compare to semaglutide and tirzepatide in research?
- Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
- Is retatrutide available for human use?
- No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
- Is telehealth legal in Rhode Island?
- Yes, Rhode Island has progressive telehealth laws supporting virtual healthcare. Licensed providers can offer comprehensive services including consultations and prescriptions.
- Can Rhode Islanders get prescriptions via telehealth?
- Yes, Rhode Island allows telehealth providers to prescribe medications following proper evaluation. Prescriptions are sent to your local pharmacy or delivered to your home.
- Does Rhode Island insurance cover telehealth?
- Yes, Rhode Island mandates telehealth coverage parity. Insurers must cover virtual visits at the same rate as in-person appointments for covered services.